181.99

8.44% -16.77

After Hours: 180.00 -1.99 -1.09%

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $181.99, with a volume of 1.74M. It is down -8.44% in the last 24 hours and up +234.66% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$198.76

Open:

$180.49

24h Volume:

1.74M

Relative Volume:

2.17

Market Cap:

$3.83B

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-19.85

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

-2.12%

1M Performance:

+234.66%

6M Performance:

+352.26%

1Y Performance:

+166.34%

1-Day Range:

$167.03

$186.68

1-Week Range:

$167.03

$206.71

52-Week Range:

$26.70

$206.71

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1136)

Industry

Biotechnology (633)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	181.99	4.95B	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	426.00	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.25	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.07	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	826.28	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.23	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

11:34 AM

Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating - MSN

11:34 AM

09:37 AM

Is a relief rally coming for Praxis Precision Medicines Inc. holdersQuarterly Profit Review & Safe Investment Capital Preservation Plans - newser.com

09:37 AM

09:19 AM

How analysts rate Praxis Precision Medicines Inc. stock today2025 Fundamental Recap & Low Risk Growth Stock Ideas - newser.com

09:19 AM

09:12 AM

What institutional flow reveals about Praxis Precision Medicines Inc.2025 Fundamental Recap & Weekly High Momentum Picks - newser.com

09:12 AM

08:48 AM

Is Praxis Precision Medicines Inc. stock near bottom after decline2025 Buyback Activity & AI Enhanced Trading Alerts - newser.com

08:48 AM

08:03 AM

How institutional buying supports Praxis Precision Medicines Inc. stockJuly 2025 Sector Moves & Verified Short-Term Plans - newser.com

08:03 AM

07:49 AM

Is Praxis Precision Medicines Inc. stock a contrarian buyJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - newser.com

07:49 AM

07:06 AM

Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatWeekly Risk Summary & High Yield Equity Trading Tips - newser.com

07:06 AM

06:20 AM

Applying big data sentiment scoring on Praxis Precision Medicines Inc.Bull Run & Reliable Volume Spike Trade Alerts - newser.com

06:20 AM

06:19 AM

Using Python tools to backtest Praxis Precision Medicines Inc. strategiesWeekly Volume Report & Weekly High Conviction Ideas - newser.com

06:19 AM

04:06 AM

Published on: 2025-11-03 03:06:20 - newser.com

04:06 AM

03:27 AM

Does Praxis Precision Medicines Inc. qualify in momentum factor screeningJuly 2025 Levels & Real-Time Chart Breakout Alerts - newser.com

03:27 AM

Nov 02, 2025

Published on: 2025-11-02 22:52:57 - newser.com

Nov 02, 2025

How Praxis Precision Medicines Inc. stock valuations compare to rivalsTrade Analysis Summary & Long-Term Capital Growth Strategies - newser.com

Nov 02, 2025

Nov 01, 2025

Praxis Precision Medicines prices $525M public offering - MSN

Nov 01, 2025

Published on: 2025-11-01 00:59:14 - newser.com

Nov 01, 2025

Oct 31, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 1-Year HighHere's What Happened - MarketBeat

Oct 31, 2025

Praxis Precision Medicines stock hits 52-week high at $206.36 By Investing.com - Investing.com Australia

Oct 31, 2025

Published on: 2025-10-31 03:19:21 - newser.com

Oct 31, 2025

What valuation multiples suggest for Praxis Precision Medicines Inc. stockDividend Hike & Proven Capital Preservation Tips - newser.com

Oct 31, 2025

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 31, 2025

Oct 30, 2025

Praxis Precision Medicines stock hits 52-week high at $206.36 - Investing.com

Oct 30, 2025

Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2025

Oct 29, 2025

Published on: 2025-10-29 21:58:45 - newser.com

Oct 29, 2025

What’s Happening With Praxis Stock? - Trefis

Oct 29, 2025

Does Positive Phase 3 Data for Ulixacaltamide Transform the Outlook for Praxis Precision Medicines (PRAX)? - Sahm

Oct 29, 2025